Football Star Cooper Kupp Encourages Eye Allergy Sufferers to Find the Right Tool for the Job with Pataday

Rhea-AI Summary

Alcon has launched a new campaign featuring Cooper Kupp to promote Pataday Once Daily Relief Extra Strength, an over-the-counter solution for eye allergies. Kupp shares his own experiences battling eye allergies, emphasizing the product's effectiveness in providing 24-hour relief with just one drop. Approximately 66 million Americans suffer from ocular allergies, yet only 9 million use allergy eye drops. The campaign aims to raise awareness of Pataday's benefits through multimedia content and partnerships with social media influencers, encouraging allergy sufferers to seek relief.

Positive

• Partnership with Cooper Kupp to increase awareness of Pataday, targeting 66 million Americans suffering from ocular allergies.
• Pataday Once Daily Relief Extra Strength is the first prescription-free eye allergy relief drop, enhancing market accessibility.
• Pataday positioned as the #1 doctor-recommended eye allergy itch relief brand.

Negative

• Only 9 million out of 66 million Americans suffering from ocular allergies currently use over-the-counter eye drops, indicating a potential market gap.
• Dependence on athlete sponsorships like Kupp may limit broader brand recognition outside sports circles.

• Fresh campaign highlights Cooper Kupp’s experience with eye allergies and how Pataday can provide itch relief for millions of Americans with eye allergies¹
• Partnership supports Pataday Once Daily Relief Extra Strength, the first 24-hour eye allergy itch relief drop available without a prescription in the U.S.²
• Multimedia program motivates consumers to add Pataday eye allergy drops to their allergy routine for targeted eye itch relief

FORT WORTH, Texas--(BUSINESS WIRE)-- Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced a partnership with Cooper Kupp, professional football wide receiver and MVP of the “Big Game,” to share his experience with eye allergies and help other eye allergy sufferers find relief with Pataday^® Once Daily Relief Extra Strength. This year’s campaign, The Right Tool for the Job, highlights Kupp’s personal struggle to find the right product to treat his eye allergy symptoms and how Pataday has delivered fast-acting, long-lasting, and targeted relief for his itchy allergy eyes on and off the field.

“When the seasons change, which, unfortunately, coincides with spring organized team activities (OTAs) and the dog days of training camp, my allergies flare up. In those weeks, when we’re outdoors working out, the pollen can really make my eyes itch and distract me from focusing on the small but crucial details of my work,” said Kupp. “I use Pataday Once Daily Relief Extra Strength because it puts me in control of my allergy symptoms and it’s efficient. With just one drop in each eye, I love that I can count on 24 hours of relief from itchy eyes.”

Pataday is the #1 doctor-recommended eye allergy itch relief drop brand and is available without a prescription.³ As an antihistamine eye drop, the product works right on the cells that make your eyes itch.² To highlight key product benefits and encourage consumers to consider Pataday as The Right Tool for the Job of treating itchy allergy eyes, a full-scale media campaign will run in 2022, including organic and paid social content; partnerships with social media influencers detailing their experiences with eye allergies; and a drive for consumers to learn more about and try Pataday Once Daily Relief Extra Strength.

“Alcon is thrilled to welcome Cooper Kupp to the Pataday team as a consumer advocate for an important, but often overlooked, allergy patient need,” said Harvey Brown Jr., Senior Director, Dry Eye and Ocular Health at Alcon. “Approximately 66 million Americans suffer from ocular allergies, but only 9 million use an over-the-counter allergy eye drop to relieve their symptoms.^4-7 Through this campaign, we hope to encourage eye allergy sufferers to find targeted, fast-acting relief from their eye allergy symptoms.”

Pataday Once Daily Relief Extra Strength is available in the U.S. in drug, mass and grocery stores, as well as online retailers. Alcon’s Pataday portfolio of products offers fast, long-lasting eye allergy itch relief to the U.S. population affected by allergic conjunctivitis.² Pataday Once Daily Relief Extra Strength provides a full 24 hours of eye allergy itch relief from pollen, ragweed, grass, and animal hair and dander for people ages two and older with just one drop once a day.²

For more information, visit Pataday.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. In particular, our expectations could be affected by uncertainties regarding the success of our separation and spin-off from Novartis. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements.

Forward-looking statements in this press release speak only as of the date of its filing, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 24,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

References

1. U.S. Census Bureau. 2019.
2. PAZEO^® [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2016.
3. Based on IQVIA ProVoice Survey of Physicians and Optometrists 12 months ending December 31, 2021.
4. U.S. Census Bureau (2014). US CENSUS BUREAU - Projections of the Population by Sex and Age for the United States - 2015 to 2060.
5. Singh, K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988-1994.
6. U.S. Population Census 2019. 6. Nielsen Household Panel Data Feb. 2019.
7. Nielsen Latest 52 weeks 2/6/2019.

Connect with us on
Facebook
LinkedIn

View source version on businesswire.com: https://www.businesswire.com/news/home/20220605005103/en/

Media Relations

Wes Warnock  

+ 41 589 112 111 (Geneva) 

+ 1 817 615 2501 (Fort Worth)

globalmedia.relations@alcon.com



Investor Relations 

Allen Trang

+ 41 589 112 110 (Geneva) 

+ 1 817 615 2789 (Fort Worth)

investor.relations@alcon.com

Source: Alcon Inc. Corporate

FAQ

What is the new campaign by Alcon featuring Cooper Kupp about?

The campaign promotes Pataday Once Daily Relief Extra Strength, highlighting Kupp's personal struggle with eye allergies and how the product provides relief.

What is Pataday Once Daily Relief Extra Strength?

It is an over-the-counter eye allergy relief drop that offers 24-hour relief from itchy eyes caused by allergens.

How many Americans suffer from eye allergies?

Approximately 66 million Americans suffer from ocular allergies.

What is the significance of Pataday in the market?

Pataday is the first prescription-free eye allergy relief drop available in the U.S. and is the #1 doctor-recommended brand.

How does the campaign aim to raise awareness for Pataday?

The campaign utilizes multimedia content, influencer partnerships, and personal testimonials to motivate consumers to try Pataday for eye allergy relief.